BCM
GNMK

Bridgeway Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Bridgeway Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-49,900
Closed -$354K – 1424
2019
Q1 		$354K Sell
49,900
-130,000
-72% -$856K ﹤0.01% 1122
2018
Q4 		$874K Hold
179,900
– – 0.01% 783
2018
Q3 		$1.32M Hold
179,900
– – 0.01% 766
2018
Q2 		$1.15M Hold
179,900
– – 0.01% 826
2018
Q1 		$979K Buy
+179,900
New +$894K 0.01% 850

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bridgeway Capital Management's GNMK Position: Q2 2019 in Review

Bridgeway Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2019, closing a stake of 49,900 shares — an estimated $354K sold.

Bridgeway Capital Management first reported a position in GNMK in Q1 2018 and held it in 5 quarters. The position peaked at $1.32M in Q3 2018. 106 funds tracked by Wall St. Rank hold GNMK as of Q2 2019.

  • Bridgeway Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 49,900 GenMark Diagnostics, Inc shares in Q2 2019, an estimated $354K.
  • Bridgeway Capital Management first reported a position in GenMark Diagnostics, Inc in Q1 2018 and held it in 5 quarters.
  • Bridgeway Capital Management's GenMark Diagnostics, Inc position peaked at $1.32M in Q3 2018.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.